Fulcrum Therapeutics Sees Positive Pociredir Trial Results
Fulcrum Therapeutics’ pociredir shows promise in sickle cell disease trial. The company’s clinical-stage biopharmaceutical, valued at $482 million, has seen its stock drop 19% despite positive initial results from the Phase 1b PIONEER trial. The trial found that patients in the 20 mg cohort experienced a mean absolute fetal hemoglobin increase of 9.9% at Week … Read more